secwatch.observer — SEC 8-K summary
======================================

Issuer:     ZyVersa Therapeutics, Inc. (ZVSA)
CIK:        0001859007
Form:       8-K
Filed at:   2023-11-30T23:59:59+00:00
Accession:  0001493152-23-043170
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ZyVersa Therapeutics approves 1-for-35 reverse stock split and increases authorized shares to 251M
--------------------------------------------------------------------------------

- Reverse split 1:35 effective Dec 4, 2023 at 4:01 pm ET; adjusted trading begins Dec 5 under ZVSA.
- Authorized common shares increased from 110M to 250M; total capital stock from 111M to 251M.
- Split intended to meet Nasdaq's $1.00 minimum bid price requirement for continued listing.
- No fractional shares will be issued; holders will receive rounding to nearest whole share.
- Proportional adjustments to equity awards, warrants, and convertible securities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223043170/0001493152-23-043170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859007/000149315223043170/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-043170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer